ANDOVER, Mass.--(BUSINESS WIRE)--March 14, 2006--TransMedics, Inc., a privately held medical device company founded in 1998 to address the unmet need for better, more effective organ transplant technologies, announced today that it has raised $29.75 million in Series C financing. The company's breakthrough, investigational technology, the Organ Care System, is the first organ transport system designed to maintain organs in a warm, functioning state outside of the body to optimize their health, enabling living organ transplant. The goal of the system is to ensure the healthiest possible organs for transplant and to increase the number of usable transplant organs. TransMedics recently initiated the European PROTECT trial, designed to evaluate the safety and performance of the Organ Care System for heart transplants.
The investment round was led by global venture capital group 3i Group, with additional investments from prior investors Alta Partners, CB Health Ventures, Flagship Ventures, Posco BioVentures, Sagamore Bioventures, Sherbrooke Capital and VantagePoint Venture Partners. The capital will be used to accelerate TransMedics' growth by continuing the PROTECT trial, and initiating new trials in Europe and the U.S. Additionally, it will be used for commercialization of the Organ Care System, and to extend the platform to other organs beyond the heart, such as the lung, liver and kidneys.
"TransMedics is currently on track to meet our development goals, including European market approval early in 2007," said Dr. Waleed Hassanein, president and CEO of TransMedics, Inc. " We're pleased with the PROTECT trial's progress so far and have plans to expand our clinical studies beyond Germany and the UK in the near future."
"TransMedics' Organ Care System is designed to meet a growing global need - currently expected to surpass 200,000 by the end of the decade - for donor organs that arrive at their destination in a healthy state," said Allan Ferguson, Senior Partner of lead investor 3i Group. "We're pleased with the initial success reported in the early stages of the PROTECT trial, and we believe the Organ Care System is poised to transform the landscape of organ transplantation."
The Growing Need for New Transplant Technologies
The number of people requiring a life-saving transplant continues to rise faster than the number of available donors. Of the 91,000 people in the U.S. currently waiting for a donor organ, only a third will receive a transplant, while nearly 7,000 will die each year while waiting for an organ. This means approximately 17 transplant candidates die each day while waiting to receive a donor organ. The situation is equally serious in Europe. For example, of the 12,000 people in Germany currently waiting for a donor organ, only a third will receive a transplant. Nearly 1,000 transplant candidates die each year. While there has been some progress in increasing donation rates in the last year, the demand for donor organs is increasing as well. In the UK today, there are 6,000 patients waiting for an organ transplant. However, fewer than 3,000 transplants are carried out annually; thus the transplant list continues to get longer. More than half of all hearts that have been consented for donation still go unused. The limits of current cold preservation methods contribute to this problem.
Prof. Dr. Dr. Reiner Korfer, medical director of the Heart and Diabetes Centre in North Rhine Westphalia stated: "Our initial experience with the TransMedics Organ Care System has been very encouraging. We believe that maintaining hearts in a beating, functioning state during transport, will result in decreased risk of organ damage and its associated complications."
About TransMedics, Inc.
Headquartered in Andover, Massachusetts, TransMedics is a privately held medical device company founded in 1998 to address the unmet need for better, more effective organ transplant technologies. The Company has developed the first and only system that allows a new type of organ transplant, called a living organ transplant. This breakthrough, investigational technology, called an Organ Care System, is designed to maintain organs in a warm functioning state outside of the body during transport from organ donor to recipient. The goal of TransMedics' technology is to improve outcomes and increase organ availability for the growing population of patients with end-stage organ failure in need of a transplant, bridging the ever-widening gap between the number of organs and the number of recipients awaiting transplants.
TransMedics' mission is to enable more patients with end-stage organ failure to benefit from the accepted medical standard of care--successful transplantation. The TransMedics Organ Care System is designed to help to improve the health of organs being transplanted as well as increase the number of organs available, improving outcomes, and reducing recovery time, hospital stays and reliance on ongoing medical therapies. For more information, visit www.TransMedics.com.
3i is a leading international venture capital and private equity firm that was founded in 1945 to invest in buyouts, growth capital and venture capital in order to create market-leading companies. Since its inception, 3i has invested over $32 billion worldwide and has a total staff of 700 employees operating in 14 countries.
In the U.S., 3i invests in both early and late stage technology companies in the software, communications, semiconductor and healthcare sectors. 3i partners leverage over 150 years of investing and operating experience and a global network to create value for their portfolio and investment partners. With a proven track record and knowledge of venture capital investing, 3i provides hands on support and guidance in building and scaling successful businesses.
3i is a successful active early and late stage investor. We have 10 partners in our U.S. offices in Menlo Park, CA. and Waltham, MA. During 2005, 3i's VC healthcare team invested in Carmel Pharma, Ulthera, Endosense, Triage wireless and elbion. It has been a strong year for successful realisations with trade sales of Arakis, NeoPharma, PharMetrics, SpineNext and Arexis and IPOs for ProStrakan, Arpida, Paion, Jerini, Phoqus and Ardana. For more information, go to: http://www.3i.com/.
Contacts in the US
Ariane Doud, 617-520-7114
Katja Gehrt, 650-470-3210
David Kolstad, 978-552-0927
Vice President of Marketing
Contact in the UK
Yvonne Alexander, +44 (0) 20 7067 0725